{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=myeloid+progenitor+cell+transplantation&page=14",
    "query": {
      "intervention": "myeloid progenitor cell transplantation",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 413,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=myeloid+progenitor+cell+transplantation&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=myeloid+progenitor+cell+transplantation&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:48:17.774Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00346359",
      "title": "Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2006-03",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2010-05-14",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346359"
    },
    {
      "nct_id": "NCT00469014",
      "title": "Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "OTHER"
        },
        {
          "name": "Thymoglobulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 72,
      "start_date": "2006-09",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00469014"
    },
    {
      "nct_id": "NCT03881735",
      "title": "Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blasts Under 5 Percent of Peripheral Blood White Cells",
        "Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level",
        "IDH2 Gene Mutation",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Enasidenib",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-02",
      "completion_date": "2022-11-19",
      "has_results": false,
      "last_update_posted_date": "2021-03-10",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • East Hills, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "East Hills",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03881735"
    },
    {
      "nct_id": "NCT05309733",
      "title": "A Long-term Follow-up Study of Patients Who Received VOR33",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "VOR33",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Vor Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2022-04-15",
      "completion_date": "2025-05-28",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Miami, Florida • Bethesda, Maryland + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309733"
    },
    {
      "nct_id": "NCT00006363",
      "title": "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Acute Basophilic Leukemia",
        "Adult Acute Eosinophilic Leukemia",
        "Adult Acute Erythroid Leukemia (M6)",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Childhood Acute Basophilic Leukemia",
        "Childhood Acute Eosinophilic Leukemia",
        "Childhood Acute Erythroleukemia (M6)",
        "Childhood Acute Megakaryocytic Leukemia (M7)",
        "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Childhood Acute Monoblastic Leukemia (M5a)",
        "Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)",
        "Childhood Acute Monocytic Leukemia (M5b)",
        "Childhood Acute Myeloblastic Leukemia With Maturation (M2)",
        "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Childhood Acute Myelomonocytic Leukemia (M4)",
        "Childhood Myelodysplastic Syndromes",
        "de Novo Myelodysplastic Syndromes",
        "Untreated Adult Acute Myeloid Leukemia",
        "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "valspodar",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "clinical observation",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "15 Years to 59 Years"
      },
      "enrollment_count": 720,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006363"
    },
    {
      "nct_id": "NCT03709576",
      "title": "Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        },
        {
          "name": "transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 3,
      "start_date": "2018-07-18",
      "completion_date": "2019-07-22",
      "has_results": true,
      "last_update_posted_date": "2020-12-16",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709576"
    },
    {
      "nct_id": "NCT01532635",
      "title": "A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Leukemia",
        "Acute Lymphoblastic Leukemia",
        "ALL",
        "Acute Myelogenous Leukemia",
        "AML",
        "Chronic Lymphocytic Leukemia",
        "CLL",
        "Lymphoma",
        "Hodgkin's Lymphoma",
        "Non-hodgkin's Lymphoma",
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Donor Lymphocyte Infusion (DLI)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide (CY)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Stem Cell Transplant (HSCT)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2012-03",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01532635"
    },
    {
      "nct_id": "NCT01839240",
      "title": "Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-06-06",
      "completion_date": "2019-08-16",
      "has_results": false,
      "last_update_posted_date": "2020-05-15",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01839240"
    },
    {
      "nct_id": "NCT00006040",
      "title": "Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "yttrium Y 90 monoclonal antibody M195",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-04",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006040"
    },
    {
      "nct_id": "NCT05357482",
      "title": "Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Beta Thalassemia"
      ],
      "interventions": [
        {
          "name": "TBI",
          "type": "RADIATION"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "briquilimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "4 Years to 100 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-05-12",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-14T16:48:17.774Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05357482"
    }
  ]
}